Pseudomonas aeruginosa Carbapenem Resistant (CDC & FDA AR Isolate Bank #0246), Bacteremia Model, LD90-100

  1. image
  2. image
  3. image
  4. image
  5. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model evaluates the antimicrobial efficacy of test articles for treatment of systemic infections with a carbapenem resistant Pseudomonas aeruginosa. Tissue microbial counts can be measured.
SPECIES
Pseudomonas aeruginosa
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
SOURCE
STRAIN SOURCE
CDC & FDA AR Isolate Bank
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 10 male or female specific-pathogen-free BALB/c mice 18 ± 2 g are used. Each animal is inoculated with an intravenously administered LD90-100 dose (1.0-2.0 x 10^8 CFU/mouse) of Pseudomonas aeruginosa (CDC & FDA AR-BANK#0246) suspended in 0.1 mL PBS. Test substance and vehicle are administered at 1 and 13 hour later (BID) or per the client’s specifications. Standard dose routes are IP, PO, IV or SC injection. Mortality is recorded daily during the following 7 days. Prevention of mortality is recorded in percentage and the significance is assessed by Fisher’s exact test. (Optional): at 8 hours after inoculation, the animals are euthanized with CO2 asphyxiation, and blood samples, lung, liver and kidney tissues can be harvested from each of the test animals for bacterial enumeration. The removed tissues are homogenized in 1 mL PBS, pH 7.4, with a Polytron homogenizer. Homogenates, 0.1 mL, are diluted 10-fold and plated on suitable agar for colony count (CFU/g) determination.
TURNAROUND TIME
STANDARD
25 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences